Pharmaceuticals

Chimin

Chimin released FY2025 annual earnings on April 29 After-Market (BJT), actual revenue CNY 685.96 M, actual EPS CNY -0.47

Chimin released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 163.1 M, actual EPS CNY -0.05

Chimin released FY2025 Q4 earnings on April 29 After-Market (BJT), actual revenue CNY 141.24 M, actual EPS CNY -0.3246

Chimin to Release FY2025 Earnings Report on April 28 After-Market (BJT)

Chimin to Release FY2026 Q1 Earnings on April 28 After-Market (BJT)

Chimin released FY2025 9 Months Earnings on October 30 Pre-Market (BJT), actual revenue CNY 544.72 M, actual EPS CNY -0.1424

Chimin released FY2025 Q3 earnings on October 30 Pre-Market (BJT), actual revenue CNY 178.27 M, actual EPS CNY -0.0472

Chimin to Release FY2025 Q3 Earnings on October 31, Pre-Market BJT

Chimin released FY2025 Q2 earnings on August 20 During-Market (BJT), actual revenue CNY 185.43 M, actual EPS CNY -0.0651

Chimin released FY2025 Semi-Annual earnings on August 20 During-Market (BJT), actual revenue CNY 366.45 M, actual EPS CNY -0.0999

Chimin to Release FY2025 Semi-Annual Earnings on August 21, 2025 (BJT)

Jiming Health Expected Net Profit Loss in First Half of 2025

Jiming Health Plans to Invest 150 Million Yuan in Hubei Changhe Intelligent Technology Venture Development Partnership

Jiming Health and Dobio Biotech Sign Strategic Collaboration Agreement for New Drug Development

Jiming Health Repurchased 1.7055 Million Shares

Chimin released FY2024 earnings on April 28 After-Market (BJT), actual revenue CNY 775.73 M (forecast CNY 1.62 B), actual EPS CNY -0.11

Chimin released FY2025 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 181.02 M, actual EPS CNY -0.03

Chimin released FY2024 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY 93.06 M, actual EPS CNY -0.1501

Chimin to Release FY2024 Earnings on April 29 After-Market (BJT), Forecast Revenue CNY 1.62 B

Chimin FY2025 Q1 Earnings Release Scheduled for April 29 After-Market BJT

301017

600488

301584

000788

301408

600594

603222

600829

301015

603122

China's A-share pharmaceutical industry chain continues to strengthen, with Chimin and CMC hitting the daily limit, following TJPC, YIBAI PHARMACEUTICAL, and PKU HEALTHCARE also hitting the daily limit. Previously, Huaren Health, Baheal Medical, SYPM, INNOSTIC, and HRPC, among other stocks, rose more than 5%

Wallstreetcn

SYPM

TJPC

C&D INNOSTIC

PKU HEALTHCARE

Huaren Health

YIBAI PHARMACEUTICAL

HRPC

Baheal Medical

Chimin announced that the company will repurchase shares through centralized bidding trading on March 28, 2025, with a repurchase amount of 100 million to 200 million yuan, and the period is 12 months from the date of the board of directors' approval, for the employee stock ownership plan or equity incentive. As of October 31, 2025, the company has repurchased a total of 2.0055 million shares, accounting for 0.38% of the total share capital, with a total payment of 12.089 million yuan, and the repurchase price range is 5.87-6.13 yuan/share. No repurchase was implemented in October 2025

Zhitong

Chimin: Plans to repurchase shares worth 100 million to 200 million yuan, with a total repurchase of 12.089 million yuan already completed

Chimin Health Management Co., Ltd. plans to repurchase 2.0055 million shares through a share repurchase plan on March 28, 2025, accounting for 0.3819% of the total share capital. The repurchase price will not exceed 10 yuan per share, with a total fund amount of 100 million to 200 million, and the repurchase period is 12 months. As of September 30, 2025, 12.089 million yuan has been paid, with purchase prices ranging from 5.87 yuan to 6.13 yuan. The company reminds investors to pay attention to risks

Chimin disclosed the progress of its share repurchase, having repurchased a total of 2.0055 million shares

Chimin issued a risk warning announcement, stating that its stock price trend is significantly deviating from its operating performance. The company's stock closed at the daily limit today, with a turnover rate of 16.96%, and has accumulated a rise of 33.78% from September 8 to 11. However, the increase over the past 30 trading days deviates from the Shanghai Composite Index by 94.72%, and the company's net profit for the fiscal year 2024 is projected to be -59.7117 million yuan, with a net profit of -52.6959 million yuan for the first half of 2025, indicating performance losses, unchanged main business, and a risk of rapid decline

Chimin: Currently, the stock price trend is significantly diverging from the operating performance trend

300204

688068

688202

300436

688166

The concept of innovative drugs has rebounded, with Chimin gaining 6 limit-ups in 12 days, Staidson BioPharm rising over 7%, Hotgen increasing over 5%, and stocks like Medicilon, Cosunter, and BrightGene also seeing gains

Staidson BioPharm

Hotgen

Medicilon

Cosunter

BrightGene

According to the Zhitong Finance APP, Chimin announced that its shareholder Shuangge Group plans to reduce its holdings of the company's shares by a total of no more than 15.7527 million shares through centralized bidding and block trading, which is no more than 3% of the company's total share capital

Chimin's shareholder Shuangge Group plans to reduce its holdings by no more than 3%

688356

688658

688221

002294

688222

Innovative drug concept stocks are repeatedly active, Chimin hit the daily limit, JENKEM rose over 10%, YKYY, Nossan, Frontier Biotechnologies, Salubris, and HitGen followed suit

JENKEM

YKYY

Froniter Biotechnologies

Salubris

HitGen

Innovative drug concept stocks are repeatedly active, Chimin hits the daily limit

601869

06869

603228

High-priced stocks experienced a significant decline, with more than ten popular high-priced stocks such as Kinwong, YOFC, and Chimin hitting the limit down, while over 30 stocks including Tianfu Communication and Hua Hong Company fell more than 10%

YOFC

Kinwong

601916

02016

On August 25, 2025, Chimin Health Management Co., Ltd. announced that its controlling shareholder, Shuangge Group, pledged 45 million shares of the company to the Taizhou branch of CZBANK on August 20, accounting for 35.16% of its holdings and 8.57% of the total share capital, for the purpose of supplementing the pledge. As of the announcement date, Shuangge Group and its concerted parties collectively held 44.52% of the total share capital, with the cumulative pledged shares accounting for 67.81% of their holdings and 30.19% of the total share capital

CZBANK

Chimin: The controlling shareholder Shuangge Group has pledged part of its shares

Chimin announced that the company's stock increased by 53.78% from August 13 to August 19, 2025, and has triggered abnormal trading twice in a row. On August 20, the stock hit the daily limit again, with a turnover rate of 31.31%. The company's fundamentals have not undergone significant changes, indicating an overheated market sentiment and irrational speculation, resulting in considerable trading risks. The net profit for 2024 is expected to be -59.7117 million yuan, and the estimated net profit for the first half of 2025 is projected to be between -55 million yuan and -46 million yuan, facing losses

Chimin: The stock has accumulated a rise of 53.78%

Chimin(603222.SH)